Thalidomide: A review of approved and investigational uses (Q35128432)

6 August 2017

1 reference

title

Thalidomide: a review of approved and investigational uses (English)

1 reference

6 August 2017

Thalidomide: A review of approved and investigational uses (English)

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80085-1

2 January 2024

0 references

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80085-1

2 January 2024

author name string

Christopher McCoy

2

1 reference

6 August 2017

S. James Matthews

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12749503

2 January 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12749503

2 January 2024

publication date

1 February 2003

1 reference

full work available at URL

6 August 2017

https://api.elsevier.com/content/article/PII:S0149291803800851?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80085-1

https://api.elsevier.com/content/article/PII:S0149291803800851?httpAccept=text/plain

2 January 2024

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80085-1

2 January 2024

published in

Clinical Therapeutics

1 reference

6 August 2017

25

1 reference

6 August 2017

2

1 reference

6 August 2017

342-395

1 reference

THALIDOMIDE AND CONGENITAL ABNORMALITIES

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

THALIDOMIDE IN THE TREATMENT OF LEPRA REACTIONS

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Improvements in Solubility and Stability of Thalidomide upon Complexation with Hydroxypropyl-β-Cyclodextrin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Enantiomers of thalidomide: blood distribution and the influence of serum albumin on chiral inversion and hydrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Determination of thalidomide by high performance liquid chromatography: methodological strategy for clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide does not alter estrogen-progesterone hormone single dose pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide dose proportionality assessment following single doses to healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG protocol 251. AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide treatment for chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

High-performance liquid chromatographic assay of plasma thalidomide: stabilization of specimens and determination of a tentative therapeutic range for chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Low bioavailability of rectally administered thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

The Influence of Thalidomide on the Clinical and Immunologic Manifestation of Erythema Nodosum Leprosum

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M. leprae-induced TNFalpha production in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide in toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Studies on the anti-inflammatory properties of thalidomide: effects on polymorphonuclear leukocytes and monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Inhibition of PMN leukocytes chemotaxis by thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

The immunomodulatory effects of thalidomide on human immunodeficiency virus-infected children

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Erythema nodosum in leprosy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide in the treatment of erythema nodosum leprosum. With a note on selected laboratory abnormalities in erythema nodosum leprosum

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

The treatment of lepra reaction in lepromatous leprosy. Fifteen years' experience with thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Cutaneous graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide for the treatment of chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Response to thalidomide therapy in refractory chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide in children undergoing bone marrow transplantation: series at a single institution and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Treatment of cutaneous and pulmonary sarcoidosis with thalidomide.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Cutaneous sarcoidosis successfully treated with low doses of thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Immune stimulation in scleroderma patients treated with thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide in actinic prurigo

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Sequential combined therapy with thalidomide and narrow-band (TL01) UVB in the treatment of prurigo nodularis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide for recurrent erythema multiforme

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Erosive lichen planus: dramatic response to thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Lichen planopilaris treated with thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide in refractory and relapsing multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide and dexamethasone combination for refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide in the management of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide for previously untreated indolent or smoldering multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Treatment of Waldenstrom's macroglobulinemia with thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide for the treatment of patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Efficacy and safety of thalidomide in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide treatment in myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

1 reference

7 January 2021

The treatment of advanced renal cell cancer with high-dose oral thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Phase II trial of thalidomide for patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide as an anti-angiogenic agent in relapsed gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Activity of thalidomide in AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Phase II evaluation of thalidomide in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide in patients with cachexia due to terminal cancer: preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide as therapy for human immunodeficiency virus-related oral ulcers: a double-blind placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Recurrent aphthous ulcer in patient infected with human immunodeficiency virus: successful treatment with thalidomide.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide for the Treatment of Acquired Immunodeficiency Syndrome–Associated Refractory Oral Ulcers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Treatment of aphthae with thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Elevated levels of interferon gamma, tumor necrosis factor alpha, interleukins 2, 4, and 5, but not interleukin 10, are present in recurrent aphthous stomatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide increases human keratinocyte migration and proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: use of neurophysiological studies to detect thalidomide neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide Responsiveness in an Infant With Behçet's Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Behçet's disease in UK children: clinical features and treatment including thalidomide.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Successful treatment of idiopathic colitis and proctitis using thalidomide in persons infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide-induced normalization of serum ALT levels in a patient with hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Inflammatory pseudotumor causing small bowel obstruction and mimicking lymphoma in a patient with AIDS: clinical improvement after initiation of thalidomide treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Effective treatment of oral erosive lichen planus with thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide: a novel therapy for microsporidiosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide for the treatment of AIDS-associated wasting

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Clinical and immunological benefit of adjuvant therapy with thalidomide in the treatment of tuberculosis disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Complete resolution of reflex sympathetic dystrophy with thalidomide treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide therapy for recalcitrant systemic onset juvenile rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

TNFalpha and response of treatment-resistant adult-onset Still's disease to thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Mechanism of action in thalidomide teratogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Does thalidomide cause second generation birth defects?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Toxicity and Teratogenicity of Optical Isomers of Thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Adverse reactions to thalidomide in patients infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide hypersensitivity in AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide neuropathy: a clinical electrophysiological, and histological follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide neuropathy: an electrophysiologic study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide neuropathy in patients treated for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Development of polyneuropathy during thalidomide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide-induced neuropathy and genetic differences in drug metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Deep venous thrombosis and thalidomide therapy for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Hypothyroidism in patients with multiple myeloma following treatment with thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide-associated hepatitis: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide-induced amenorrhoea: two cases

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Thalidomide impairs insulin action on glucose uptake and glycogen synthesis in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980085-1

7 January 2021

Results of a double blind study of the influence of thalidomide on the lepra reaction

5

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80085-1

The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species

2 January 2024

26

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80085-1

Thalidomide induces imbalances in T-lymphocyte sub-populations in the circulating blood of healthy males

2 January 2024

46

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80085-1

Thalidomide is an inhibitor of angiogenesis

2 January 2024

48

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80085-1

Prognostic value of bone marrow angiogenesis in multiple myeloma

2 January 2024

51

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80085-1

Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation

2 January 2024

53

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80085-1

WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients

2 January 2024

64

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80085-1

Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation

2 January 2024

72

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80085-1

Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide

2 January 2024

80

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80085-1

Recalcitrant pyoderma gangrenosum treated with thalidomide

2 January 2024

91

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80085-1

Thalidomide treatment of resistant or relapsed multiple myeloma patients

2 January 2024

98

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80085-1

Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma

2 January 2024

100

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80085-1

Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma

2 January 2024

101

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80085-1

Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma

2 January 2024

108

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80085-1

Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy

2 January 2024

115

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80085-1

Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study

2 January 2024

151

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80085-1

Peripheral neuropathy in HIV disease

2 January 2024

207

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80085-1

Thalidomide and thrombosis in patients with multiple myeloma

2 January 2024

214

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80085-1

2 January 2024

Identifiers

1 reference

6 August 2017

1 reference